BIO-RAD LABORATORIES, INC. acquires AbD Serotec (division of MorphoSys AG)
Snapshot
BIO-RAD LABORATORIES, INC. acquired AbD Serotec (division of MorphoSys AG) for $62.2 million total consideration (net of cash received of $7.3 million) in January 2013. The transaction was structured as all cash. AbD Serotec (division of MorphoSys AG) is a Germany / United Kingdom (MorphoSys AG division)-based Life Science business.
- Acquirer
- BIO-RAD LABORATORIES, INC.
- Target
- AbD Serotec (division of MorphoSys AG)
- Value
- $62.2 million total consideration (net of cash received of $7.3 million)
- Date
- January 2013
- Type
- carve-out
- Status
- ready
The deal at a glance
About this deal
BIO-RAD LABORATORIES, INC. acquired AbD Serotec (division of MorphoSys AG) for $62.2 million total consideration (net of cash received of $7.3 million), a transaction completed in January 2013, structured as all cash. The deal was a carve-out.
AbD Serotec (division of MorphoSys AG) operates in Life Science, is based in Germany / United Kingdom (MorphoSys AG division). AbD Serotec, acquired from MorphoSys AG, brought a comprehensive catalog of research antibodies to Bio-Rad's Life Science business.
We believe that with AbD Serotec's comprehensive catalog of antibodies it complements Bio-Rad's Life Science offerings.
Comprehensive antibody catalog expanding Bio-Rad's Life Science reagent portfolio. Adds antibody reagents to the Life Science segment. Life Science segment
No advisory firms have been disclosed for this transaction.